IDEAYA Reports Encouraging Clinical Activity From Darovasertib And Crizotinib Phase 1/2 Trial

IDEAYA Biosciences, Inc. (IDYA) issued a clinical data update for the phase 1/2 trial evaluating darovasertib and crizotinib synthetic lethal combination in metastatic uveal melanoma patients. The preliminary interim data includes: 100% disease control rate; ad 31% overall response rate. The company said these data provide clinical proof-of-concept for the combination treatment.

IDEAYA noted that it had cash, cash equivalents and marketable securities of approximately $386 million as of September 30, 2021, which it believes will fund its planned operations into 2025.

Shares of IDEAYA Biosciences were up 2% in pre-market trade on Tuesday.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
MTD Products Inc. is recalling 1,774 units of walk-behind self-propelled lawn mowers for potential risk of fire hazard, a statement by the U.S. Consumer Product Safety Commission (CPSC) showed. The company said the lawn mower can leak fuel when it is stored in the upright (vertical) storage position to pose a fire hazard. Nike Inc. announced its plans to exit the Russian market completely following Russia's ongoing war against Ukraine, reports said. The sportswear major, with more than 100 stores in the country, had suspended operations there in March. Earlier in March, while suspending operations temporarily, the company had said its customers that it couldn't guarantee product shipments. The U.S. Food and Drug Administration unveiled its action plan to advance drug development for rare neurodegenerative diseases, including Amyotrophic Lateral Sclerosis or ALS, in five years. The FDA plans specific actions such as regulatory science initiatives, enhancements to existing programs and new policy initiatives for the purpose. It will use public-private partnerships...
Follow RTT